Literature DB >> 12384800

Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.

Shingo Ashida1, Isao Nishimori, Masanobu Tanimura, Saburo Onishi, Taro Shuin.   

Abstract

PURPOSE: Our primary goal was to determine whether increased expression of the transmembrane carbonic anhydrase (CA) isozymes in renal cell carcinoma (RCC) is regulated by the von Hippel-Lindau (VHL) gene.
METHODS: We studied mRNA expression of all three transmembrane CAs - CA IX, XII, and XIV - in 17 RCC cell lines, transformants of the wild-type VHL gene, and normal kidney tissue cultures, and then compared them with the mutation status in the VHL gene.
RESULTS: Northern blot analysis showed no detectable signal for CA XIV mRNA expression in normal and cancer cells. CA XII mRNA was ubiquitously expressed except in two cell lines. Although CA XII expression levels tended to be lower in RCC cell lines without the VHL mutation and in transformants of the wild-type VHL gene, the results were not conclusive. Significant expression of CA IX mRNA was seen in eight of 17 RCC cell lines. Among five cell lines which had no VHL mutation, four lines showed no detectable signal and one cell line showed a low amount of CA IX mRNA expression. In patients with RCC, VHL mutations and significant CA IX expression were seen in established tumor cell lines but not in primary tissue cultures from normal counterparts. Further study of methylation status showed that the 5' region in the CA9 gene was hypomethylated in all CA IX-positive cell lines and hypermethylated in all CA IX-negative cell lines. Especially, methylation status at -74 and -6 CpG sites perfectly correlated with CA IX expression.
CONCLUSIONS: These findings indicate that VHL suppresses CA IX expression but has no conclusive effect on CA XII and XIV expressions in RCC. CA IX expression is also driven by the methylation status of the CA9 gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384800     DOI: 10.1007/s00432-002-0374-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

Review 1.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

2.  Expression of carbonic anhydrase 9 at the invasion front of gastric cancers.

Authors:  J Chen; C Röcken; J Hoffmann; S Krüger; U Lendeckel; A Rocco; S Pastorekova; P Malfertheiner; M P A Ebert
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

3.  Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.

Authors:  Antti-J Kivela; Seppo Parkkila; Juha Saarnio; Tuomo-J Karttunen; Jyrki Kivela; Anna-Kaisa Parkkila; Maria Bartosova; Vojtech Mucha; Michal Novak; Abdul Waheed; William-S Sly; Hannu Rajaniemi; Silvia Pastorekova; Jaromir Pastorek
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

4.  Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.

Authors:  Naoto Kuroda; Chiaki Kawada; Kenji Tamura; Makoto Hiroi; Ondrej Hes; Michal Michal; Yukari Wada; Kaori Inoue; Masahiko Ohara; Keiko Mizuno; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

5.  Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies.

Authors:  Mubashir Hassan; Muhammad Yasir; Saba Shahzadi; Andrzej Kloczkowski
Journal:  ACS Omega       Date:  2022-06-01

Review 6.  Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer.

Authors:  Kathryn F Tonissen; Sally-Ann Poulsen
Journal:  Cancer Drug Resist       Date:  2021-06-19

7.  Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX.

Authors:  Yangguang Shao; Yan Li; Jian Zhang; Di Liu; Furong Liu; Yue Zhao; Tao Shen; Feng Li
Journal:  Nucleic Acids Res       Date:  2010-01-27       Impact factor: 16.971

8.  Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer.

Authors:  Sho Kitamoto; Seiya Yokoyama; Michiyo Higashi; Norishige Yamada; Shyuichiro Matsubara; Sonshin Takao; Surinder K Batra; Suguru Yonezawa
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

9.  Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.

Authors:  V Damiano; R Rosa; L Formisano; L Nappi; T Gelardi; R Marciano; I Cozzolino; G Troncone; S Agrawal; B M Veneziani; S De Placido; R Bianco; G Tortora
Journal:  Br J Cancer       Date:  2013-04-09       Impact factor: 7.640

10.  Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.

Authors:  L Dubois; W Landuyt; K Haustermans; P Dupont; G Bormans; P Vermaelen; P Flamen; E Verbeken; L Mortelmans
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.